Announcements
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
- Addex Convenes Annual General Meeting 2024
- Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.36 |
---|---|
High | 1.37 |
Low | 1.36 |
Bid | 1.33 |
Offer | 1.43 |
Previous close | 1.37 |
Average volume | -- |
---|---|
Shares outstanding | 184.35m |
Free float | 177.53m |
P/E (TTM) | -- |
Market cap | 11.98m CHF |
EPS (TTM) | -0.1116 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼